Rhythm Biosciences (FRA:0RY) Return-on-Tangible-Equity: -803.13% (As of Dec. 2025)


FRA:0RY Rhythm Biosciences Ltd FRA:0RY
31 GF Score
Price €0.06
! 5 Warning Signs
View Full Analysis

What is Rhythm Biosciences Return-on-Tangible-Equity?

Rhythm Biosciences FRA:0RY -3.48% 31 Return-on-Tangible-Equity is -803.13% as of Dec. 2025. GuruFocus rates FRA:0RY with a GF Score™ of 31/100. The stock has 5 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Rhythm Biosciences ranks worse than 93.3% on this metric.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Rhythm Biosciences's annualized net income for the quarter that ended in Dec. 2025 was €-2.56 Mil. Rhythm Biosciences's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €0.32 Mil. Therefore, Rhythm Biosciences's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -803.13%.

The historical rank and industry rank for Rhythm Biosciences's Return-on-Tangible-Equity or its related term are showing as below:

FRA:0RY' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -2363.58   Med: -173.48   Max: -22.67
Current: -390.11

During the past 8 years, Rhythm Biosciences's highest Return-on-Tangible-Equity was -22.67%. The lowest was -2,363.58%. And the median was -173.48%.

FRA:0RY's Return-on-Tangible-Equity is ranked worse than
93.3% of 194 companies
in the Medical Diagnostics & Research industry
Industry Median: -0.405 vs FRA:0RY: -390.11

Rhythm Biosciences  (FRA:0RY) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Rhythm Biosciences Return-on-Tangible-Equity Related Terms


Rhythm Biosciences Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Rhythm Biosciences's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Biosciences Return-on-Tangible-Equity Chart

Rhythm Biosciences Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Return-on-Tangible-Equity
Get a 7-Day Free Trial -519.95 -216.20 -127.04 -227.79 -2,048.34

Rhythm Biosciences Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -255.44 -800.94 51.91 -430.00 -803.13

FRA:0RY vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison

For the Diagnostics & Research subindustry, Rhythm Biosciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhythm Biosciences Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rhythm Biosciences's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Rhythm Biosciences's Return-on-Tangible-Equity falls into.


FRA:0RY
31GF Score
Rhythm Biosciences Ltd FRA:0RY
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rhythm Biosciences Return-on-Tangible-Equity Calculation

Rhythm Biosciences's annualized Return-on-Tangible-Equity for the fiscal year that ended in Jun. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-2.161/( (0.317+-0.106 )/ 2 )
=-2.161/0.1055
=-2,048.34 %

Rhythm Biosciences's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-2.562/( (-0.106+0.744)/ 2 )
=-2.562/0.319
=-803.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2025) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of -803.13% mean?
Rhythm Biosciences (FRA:0RY) has a Return-on-Tangible-Equity of -803.13% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Rhythm Biosciences and its competitors. According to the industry distribution chart, Rhythm Biosciences ranks #181 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 93.3%.
Is Rhythm Biosciences' Return-on-Tangible-Equity too high?
Rhythm Biosciences' current Return-on-Tangible-Equity is -803.13%. Based on the distribution chart, Rhythm Biosciences ranks #181 out of 194 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Rhythm Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Biosciences' Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Rhythm Biosciences ranks #181 out of 194 companies for Return-on-Tangible-Equity. This places Rhythm Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Rhythm Biosciences and its competitors. Rhythm Biosciences's current Return-on-Tangible-Equity is -803.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Biosciences stock overvalued right now?
Rhythm Biosciences (FRA:0RY) has a current Return-on-Tangible-Equity of -803.13%. The current Return-on-Tangible-Equity is -803.13%. Rhythm Biosciences' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Rhythm Biosciences (FRA:0RY), the current Return-on-Tangible-Equity is -803.13% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rhythm Biosciences Business Description

Other Exchanges RHY:Australia
Address 30 Flemington Road, Bio21 Institute, Parkville, Melbourne, VIC, AUS, 3010
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
31GF Score

Get the complete analysis for FRA:0RY

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.06
Price